中国社区医师
中國社區醫師
중국사구의사
Chinese Community Doctors
2014年
35期
69-70
,共2页
血液灌流%血液透析%细胞免疫功能
血液灌流%血液透析%細胞免疫功能
혈액관류%혈액투석%세포면역공능
Hemoperfusion%Hemodialysis%Cellular immune function
目的：探讨血液灌流结合血液透析对维持性血透患者细胞免疫功能的临床作用。方法：收治维持性血液透析患者40例，随机均分为单一血液透析组(HD组)与血液灌流联合血液透析组(HP+HD组)，两组均治疗8周，监测治疗前、后患者CD4、CD8及CD4/CD8的变化。结果：治疗前HD组与HP+HD组的CD4[(33.18%±5.20%)比(33.09%±4.20%)]、CD8[(35.22%±1.05%)比(34.10%±1.14%)]及CD4/CD8[(1.02±0.35)比(1.07±0.38)]差异无统计学意义(P＞0.05)；治疗8周后HD组与HP+HD组的CD4[(33.53%±6.16%)比(42.92%±8.74%)]、CD8[(33.8%±8.37%)比(22.09%±7.52%)]、CD4/CD8[(1.06±0.36)比(2.24±1.16)]，差异均有统计学意义(P＜0.05)。结论：血液灌流联合血液透析对维持性血透患者，可显著改善其细胞免疫功能，进一步提高临床疗效。
目的：探討血液灌流結閤血液透析對維持性血透患者細胞免疫功能的臨床作用。方法：收治維持性血液透析患者40例，隨機均分為單一血液透析組(HD組)與血液灌流聯閤血液透析組(HP+HD組)，兩組均治療8週，鑑測治療前、後患者CD4、CD8及CD4/CD8的變化。結果：治療前HD組與HP+HD組的CD4[(33.18%±5.20%)比(33.09%±4.20%)]、CD8[(35.22%±1.05%)比(34.10%±1.14%)]及CD4/CD8[(1.02±0.35)比(1.07±0.38)]差異無統計學意義(P＞0.05)；治療8週後HD組與HP+HD組的CD4[(33.53%±6.16%)比(42.92%±8.74%)]、CD8[(33.8%±8.37%)比(22.09%±7.52%)]、CD4/CD8[(1.06±0.36)比(2.24±1.16)]，差異均有統計學意義(P＜0.05)。結論：血液灌流聯閤血液透析對維持性血透患者，可顯著改善其細胞免疫功能，進一步提高臨床療效。
목적：탐토혈액관류결합혈액투석대유지성혈투환자세포면역공능적림상작용。방법：수치유지성혈액투석환자40례，수궤균분위단일혈액투석조(HD조)여혈액관류연합혈액투석조(HP+HD조)，량조균치료8주，감측치료전、후환자CD4、CD8급CD4/CD8적변화。결과：치료전HD조여HP+HD조적CD4[(33.18%±5.20%)비(33.09%±4.20%)]、CD8[(35.22%±1.05%)비(34.10%±1.14%)]급CD4/CD8[(1.02±0.35)비(1.07±0.38)]차이무통계학의의(P＞0.05)；치료8주후HD조여HP+HD조적CD4[(33.53%±6.16%)비(42.92%±8.74%)]、CD8[(33.8%±8.37%)비(22.09%±7.52%)]、CD4/CD8[(1.06±0.36)비(2.24±1.16)]，차이균유통계학의의(P＜0.05)。결론：혈액관류연합혈액투석대유지성혈투환자，가현저개선기세포면역공능，진일보제고림상료효。
Objective:To discuss the effect of the cellular immune function of hemoperfusion combined with hemodialysis on maintenance hemodialysis patients.Methods:40 patients with maintenance hemodialysis were selected.They were randomly divided into the single hemodialysis group(HD group)and the hemoperfusion combined with hemodialysis group(HP+HD group). Both groups were treated for eight weeks.Monitoring the changes before and after the treatment,patients with CD4,CD8 and CD4/CD8.Results:Before treatment,CD4[(33.18%± 5.20%)/(33.09%± 4.20%)],CD8[(35.22%± 1.05%)/(34.10%± 1.14%)]and CD4/CD8[(1.02 ± 0.35)/(1.07 ± 0.38)] of HD group and HP+HD group had no statistical difference (P>0.05).After 8 weeks of treatment, the differences of CD4[(33.53%± 6.16%)/(42.92%± 8.74%)],CD8[(33.8%± 8.37%)/(22.09%± 7.52%)],CD4/CD8 [(1.06 ± 0.36)比(2.24 ± 1.16)] of two groups were statistically significant(P<0.05).Conclusion:Hemoperfusion combined with hemodialysis on maintenance hemodialysis patients can significantly improve the cell immune function,and improve the therapeutic effect.
